Study on the Safety and Effects of Telisotuzumab Adizutecan in Patients Aged 12 and Older with Advanced Solid Tumors with MET Amplification
Sponsor: AbbVie
ClinicalTrials ID:NCT07196644
This clinical trial is testing the safety and effects of an investigational drug, telisotuzumab adizutecan, in patients aged 12 and older with advanced solid tumors that have a specific genetic feature called MET amplification.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The study aims to evaluate the safety and impact of telisotuzumab adizutecan, a new drug being tested for treating advanced solid tumors with MET amplification. About 125 participants, aged 12 and older, will receive the drug through an IV infusion over a period of 61.5 months. The study will take place at up to 55 locations worldwide. Participants will have regular check-ups, including medical assessments, blood tests, and questionnaires, to monitor the treatment's effects and any side effects. This trial may involve more frequent visits and tests compared to standard treatments.
Eligibility Criteria
Inclusion Criteria
- Have advanced solid tumors with a specific genetic feature called MET amplification, confirmed by specific tests.
- Be in good general health, able to carry out daily activities with minimal restrictions.
- Have measurable tumors that can be tracked using standard medical criteria.
- Have already received appropriate treatments for their cancer type and stage, but have no other satisfactory treatment options available.
- If the cancer has spread to the brain, it must not be causing symptoms or must be stable after treatment.
Exclusion Criteria
- Have a history or current condition of lung disease that required steroid treatment.
- Have any major life-threatening conditions and must have a life expectancy of at least 12 weeks.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| City of Hope National Medical Center /ID# 275613 | 91010 | Duarte | California |
| Valkyrie Clinical Trials /ID# 275547 | 90067 | Los Angeles | California |
| Yale University School of Medicine /ID# 275978 | 06510 | New Haven | Connecticut |
| Florida Cancer Specialists - North /ID# 277137 | 33705 | St. Petersburg | Florida |
| Northwestern University Feinberg School of Medicine /ID# 276436 | 60611-2927 | Chicago | Illinois |
| University of Chicago Medical Center /ID# 275342 | 60637 | Chicago | Illinois |
| START Midwest /ID# 276603 | 49546 | Grand Rapids | Michigan |
| Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 275999 | 10065 | New York | New York |
| Duke Cancer Institute /ID# 275604 | 27710 | Durham | North Carolina |
| The University of Texas MD Anderson Cancer Center /ID# 275663 | 77030 | Houston | Texas |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.